Internal Reference Number: FOI_7025
Date Request Received: 16/02/2023 00:00:00
Date Request Replied To: 08/03/2023 00:00:00
This response was sent via: By Email
Request Summary: Lung cancer
Request Category: Companies
| Question Number 1: In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with: • Afatinib • Alectinib • Amivantamab • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Brigatinib • Ceritinib • Crizotinib • Dacomitinib • Dabrafenib with Trametinib • Durvalumab • Erlotinib • Gefitinib • Lorlatinib • Mobocertinib • Nintedanib with Docetaxel • Nivolumab • Osimertinib • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Pemetrexed with Carboplatin/Cisplatin • Pralsetinib • Selpercatinib • Sotorasib • Tepotinib • Vinorelbine with Carboplatin/Cisplatin • Any other active systemic anti-cancer therapy (SACT) • Palliative care only | |
| Answer To Question 1: • Afatinib 0 • Alectinib <5 • Amivantamab 0 • Atezolizumab monotherapy <5 • Atezolizumab with chemotherapy 0 • Brigatinib <5 • Ceritinib 0 • Crizotinib <5 • Dacomitinib 0 • Dabrafenib with Trametinib <5 • Durvalumab <5 • Erlotinib 0 • Gefitinib <5 • Lorlatinib <5 • Mobocertinib 0 • Nintedanib with Docetaxel <5 • Nivolumab 0 • Osimertinib 10 • Pembrolizumab monotherapy 12 • Pembrolizumab with chemotherapy 6 • Pemetrexed with Carboplatin/Cisplatin 6 • Pralsetinib 0 • Selpercatinib 0 • Sotorasib <5 • Tepotinib 0 • Vinorelbine with Carboplatin/Cisplatin <5 • Any other active systemic anti-cancer therapy (SACT) 0 • Palliative care only - unable to answer | |
| Question Number 2: In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs: • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Durvalumab • Nivolumab • Osimertinib • Pembrolizumab (Keytruda) Mono • Pembrolizumab (Keytruda) with Chemotherapy • Tepotinib • Other active systemic anti-cancer therapy (SACT) • Palliative care only | |
| Answer To Question 2: • Atezolizumab monotherapy <5 • Atezolizumab with chemotherapy 0 • Durvalumab <5 • Nivolumab 0 • Osimertinib 0 • Pembrolizumab (Keytruda) Mono <5 • Pembrolizumab (Keytruda) with Chemotherapy 0 • Tepotinib 0 • Other active systemic anti-cancer therapy (SACT) <5 • Palliative care only - unable to answer | |
| To return to the list of all the FOI requests please click here |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
